Barrett's oesophagus with no dysplasia is best managed with which surveillance strategy?

Barrett's oesophagus with no dysplasia is best managed with which surveillance strategy?

• A. Endoscopic surveillance every year
• B. Endoscopic surveillance every 2 years
• C. Endoscopic surveillance with periodic biopsies
• D. Esophagectomy

Answer: (C)

The main idea here is how to monitor Barrett’s esophagus when there is no dysplasia. The goal of surveillance is to detect any development of dysplasia or early cancer so it can be treated promptly, without subjecting a patient to unnecessary, invasive procedures or overtreatment. The best approach is endoscopic surveillance that includes periodic biopsies of the Barrett’s segment. This is done using systematic sampling (the Seattle protocol) so tissue across the entire Barrett’s mucosa is checked for focal areas of dysplasia that might be missed with random or limited biopsies. Regular endoscopy with biopsies allows early detection and timely management if dysplasia develops, while avoiding excessive procedures or overtreatment. Why the other options aren’t as appropriate here: performing endoscopy every year would expose the patient to unnecessary procedures given the relatively low annual risk of progression in nondysplastic Barrett’s. Esophagectomy is far too aggressive for nondysplastic disease and is reserved for high-grade dysplasia or cancer. Endoscopic surveillance without biopsies wouldn’t reliably detect early dysplasia, which is what surveillance aims to identify. So, endoscopic surveillance with periodic biopsies best balances monitoring for progression with avoiding overtreatment.

The main idea here is how to monitor Barrett’s esophagus when there is no dysplasia. The goal of surveillance is to detect any development of dysplasia or early cancer so it can be treated promptly, without subjecting a patient to unnecessary, invasive procedures or overtreatment.

The best approach is endoscopic surveillance that includes periodic biopsies of the Barrett’s segment. This is done using systematic sampling (the Seattle protocol) so tissue across the entire Barrett’s mucosa is checked for focal areas of dysplasia that might be missed with random or limited biopsies. Regular endoscopy with biopsies allows early detection and timely management if dysplasia develops, while avoiding excessive procedures or overtreatment.

Why the other options aren’t as appropriate here: performing endoscopy every year would expose the patient to unnecessary procedures given the relatively low annual risk of progression in nondysplastic Barrett’s. Esophagectomy is far too aggressive for nondysplastic disease and is reserved for high-grade dysplasia or cancer. Endoscopic surveillance without biopsies wouldn’t reliably detect early dysplasia, which is what surveillance aims to identify.

So, endoscopic surveillance with periodic biopsies best balances monitoring for progression with avoiding overtreatment.